Drilldown: Medicines
Medicines > onset 
:
15–30 min or
Symptomatic effect within weeks; full response by 12-24 weeks or
~30 min
:
15–30 min or
Symptomatic effect within weeks; full response by 12-24 weeks or
~30 min Use the filters below to narrow your results.
generic:
brand:
classes:
Caffeine plant (1) ·
Cathinone source (1) ·
Dual orexin receptor antagonist (DORA) (3) ·
Excitantia (2) ·
PDE5 Inhibitor (1) ·
Plant Medicine (2) ·
the first approved (1) ·
[[:Category:Biologics|Biologic]] (1) ·
[[:Category:DMARDs|DMARD]] (1) ·
[[:Category:Immunosuppressants|Immunosuppressant]] (1) ·
[[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]] (1) ·
[[:Category:TNF_inhibitors|TNF-α inhibitor]] (1)
mechanism:
None (1) ·
Caffeine + theophylline + L-theanine. L-theanine (an amino acid unique to tea) modulates glutamate and produces an 'alpha-wave' calming overlay on caffeine's stimulation, hence tea's reputation as a 'cleaner' stimulant than coffee. (1) ·
Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) ·
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Primary alkaloid is (S)-(-)-cathinone, a phenylpropanolamine close kin to amphetamine. Releases dopamine and norepinephrine. Also contains cathine (=norpseudoephedrine) and norephedrine. (1) ·
Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1) ·
'"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)
uses:
None (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) ·
Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) ·
'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' (1) ·
'"`UNIQ--vote-00000669-QINU`"' (1) ·
'"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"' (1)
starting dose:
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
10 mg ~1 h before sexual activity (1) ·
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) ·
40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1) ·
5 mg PO at bedtime; may increase to 10 mg if inadequate (1) ·
A ''marduuf'' bundle (~50 g fresh leaves) chewed over a couple of hours (1) ·
One cup (~40–60 mg caffeine; about half of brewed coffee) (1)
preparations:
2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) ·
25 mg, 50 mg tablets (1) ·
40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1) ·
5 mg, 10 mg tablets (1) ·
5 mg, 10 mg, 15 mg, 20 mg tablets (1) ·
Dried leaves, infused. Six major processings: white, green, yellow, oolong, black, pu-erh (1) ·
Fresh leaves and tender twigs chewed; degrades on drying (1)
fda max:
routes:
onset: (Click arrow to add another value)
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 7 results in range #1 to #7.